{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T01:14:04Z","timestamp":1794100444819,"version":"4.8.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005565","name":"Johnson & Johnson Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ebiom.2025.105940","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T07:10:48Z","timestamp":1758611448000},"page":"105940","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer's disease: a phase 1b\/2a, multicentre, double-blind, randomised, placebo-controlled study"],"prefix":"10.1016","volume":"120","author":[{"given":"Olivier","family":"Sol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Mermoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merja","family":"Hallikainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhir","family":"Kurl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha","family":"Rinne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Dautzenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everard G.B.","family":"Vijverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Mummery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"B\u00f6rjesson-Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Jonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Pennington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Vukicevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Gollwitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Fiorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Hickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Hliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoriia","family":"Gerasymchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Wagg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"L\u00ea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iva","family":"Kezic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennert","family":"Steukers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gallen","family":"Triana-Baltzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1678-8573","authenticated-orcid":false,"given":"Clara","family":"Theunis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9387-5951","authenticated-orcid":false,"given":"Johannes","family":"Streffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4020-8226","authenticated-orcid":false,"given":"Marie","family":"Kosco-Vilbois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pfeifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1046-6408","authenticated-orcid":false,"given":"Philip","family":"Scheltens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ebiom.2025.105940_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105940_bib2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105940_bib3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105940_bib4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers","volume":"12","author":"Jack","year":"2013","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105940_bib5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","article-title":"Defining imaging biomarker cut points for brain aging and Alzheimer's disease","volume":"13","author":"Jack","year":"2017","journal-title":"Alzheimers Dement"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105940_bib6","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/brain\/aww023","article-title":"Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages","volume":"139","author":"Schwarz","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.ebiom.2025.105940_bib7","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","article-title":"Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline","volume":"28","author":"Ossenkoppele","year":"2022","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.ebiom.2025.105940_bib8","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105940_bib9","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1093\/brain\/awad188","article-title":"Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics","volume":"146","author":"Hampel","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.ebiom.2025.105940_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.862369","article-title":"Amyloid-related imaging abnormalities with anti-amyloid antibodies for the treatment of dementia due to Alzheimer's disease","volume":"13","author":"Withington","year":"2022","journal-title":"Front Neurol"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105940_bib11","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/s43587-023-00410-4","article-title":"Detection and treatment of Alzheimer's disease in its preclinical stage","volume":"3","author":"Rafii","year":"2023","journal-title":"Nat Aging"},{"issue":"12","key":"10.1016\/j.ebiom.2025.105940_bib12","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1093\/brain\/awac229","article-title":"Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease","volume":"145","author":"Tanner","year":"2022","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105940_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-34129-4","article-title":"Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer's disease","volume":"13","author":"Pichet Binette","year":"2022","journal-title":"Nat Commun"},{"issue":"24","key":"10.1016\/j.ebiom.2025.105940_bib14","doi-asserted-by":"crossref","first-page":"20522","DOI":"10.1074\/jbc.M111.323279","article-title":"Paired Helical Filaments from Alzheimer Disease brain induce intracellular accumulation of Tau protein in aggresomes","volume":"287","author":"Santa-Maria","year":"2012","journal-title":"J Biol Chem"},{"issue":"19","key":"10.1016\/j.ebiom.2025.105940_bib15","doi-asserted-by":"crossref","first-page":"12845","DOI":"10.1074\/jbc.M808759200","article-title":"Propagation of Tau misfolding from the outside to the inside of a cell","volume":"284","author":"Frost","year":"2009","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105940_bib16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nrn2786","article-title":"Prion-like mechanisms in neurodegenerative diseases","volume":"11","author":"Frost","year":"2010","journal-title":"Nat Rev Neurosci"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105940_bib17","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/cpt.2875","article-title":"Donanemab population pharmacokinetics, amyloid plaque reduction, and safety in participants with Alzheimer's disease","volume":"113","author":"Gueorguieva","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.ebiom.2025.105940_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072301","article-title":"Efficacy and safety of A liposome-based vaccine against protein Tau, assessed in Tau.P301L mice that model tauopathy","volume":"8","author":"Theunis","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ebiom.2025.105940_bib19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.conb.2021.03.003","article-title":"A current view on Tau protein phosphorylation in Alzheimer's disease","volume":"69","author":"Wegmann","year":"2021","journal-title":"Curr Opin Neurobiol"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105940_bib20","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/0896-6273(93)90057-X","article-title":"Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding","volume":"10","author":"Bramblett","year":"1993","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105940_bib21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/nan.12084","article-title":"Phosphorylation of tau protein at sites Ser (396-404) is one of the earliest events in Alzheimer's disease and Down syndrome","volume":"40","author":"Mondrag\u00f3n-Rodr\u00edguez","year":"2014","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105940_bib22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13024-021-00460-5","article-title":"\u201cDon't Phos Over Tau\u201d: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer's disease and other tauopathies","volume":"16","author":"Xia","year":"2021","journal-title":"Mol Neurodegener"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105940_bib23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1021\/bc970183n","article-title":"Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses","volume":"9","author":"Guan","year":"1998","journal-title":"Bioconjug Chem"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105940_bib24","first-page":"507","article-title":"Enhancement of immunogenicity of tumour virus antigen by liposomes: the effect of lipid composition","volume":"58","author":"Bakouche","year":"1986","journal-title":"Immunology"},{"key":"10.1016\/j.ebiom.2025.105940_bib25","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2119\/molmed.2016.00218","article-title":"A modification-specific peptide-based immunization approach using CRM197 carrier protein: development of a selective vaccine against pyroglutamate A\u03b2 peptides","volume":"22","author":"Vingtdeux","year":"2016","journal-title":"Mol Med"},{"issue":"12","key":"10.1016\/j.ebiom.2025.105940_bib26","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.4161\/hv.26109","article-title":"Protein carriers of conjugate vaccines: characteristics, development, and clinical trials","volume":"9","author":"Pichichero","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105940_bib27","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/brain\/awac407","article-title":"Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration","volume":"146","author":"Gonzalez-Ortiz","year":"2023","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105940_bib28","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1093\/brain\/awaa286","article-title":"Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease","volume":"143","author":"Mattsson-Carlgren","year":"2020","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.ebiom.2025.105940_bib29","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ebiom.2025.105940_bib30","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s43587-021-00070-2","article-title":"ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease","volume":"1","author":"Novak","year":"2021","journal-title":"Nat Aging"},{"key":"10.1016\/j.ebiom.2025.105940_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104923","article-title":"Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology: a post hoc analysis of the \u201cADAMANT\u201d randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial","volume":"99","author":"Cullen","year":"2024","journal-title":"EBioMedicine"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425003846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425003846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:58:38Z","timestamp":1773161918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396425003846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":31,"alternative-id":["S2352396425003846"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.105940","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer's disease: a phase 1b\/2a, multicentre, double-blind, randomised, placebo-controlled study","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.105940","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AC Immune SA; Johnson@Johnson Innovative Medicine. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105940"}}